Anti-Human IL-17 (Bimekizumab) – Fc Muted™ - 500 µg

All|Recombinant Antibodies>Biosimilar Recombinant Antibodies|Primary Monoclonal Antibodies

2 - 8°C Wet Ice

Interleukin 17 (IL-17) is a pro-inflammatory cytokine crucial to host defense, tissue repair, pathogenesis of inflammatory disease, and progression of cancer1. IL-17 signaling is also criticalfor protection against fungal and bacterial infection2. There are six pro-inflammatory cytokines(IL-17A-F) produced by Th17 cells3. IL-17A and IL-17F share ~50% structural homology4 aswell as overlapping biological functions in chronic inflammation and adaptive immune defensefrom bacterial and fungal infection5. Additionally, they are coexpressed in immune-inflammatory diseases5. IL-17A and IL-17F drive pathogenesis in psoriasis5 and are both foundin lesional skin and inflamed synovium from patients with psoriatic arthritis4. Since dualneutralization of IL-17A and IL-17F results in lower expression of inflammation-linked genesand cytokines 4 and because targeting the IL-17 pathway has clinical efficacy5, an antibodytherapeutic designed to potently and selectively neutralize both IL-17A and IL-17F is desirable.Bimekizumab is a humanized monoclonoal antibody designed to bind at a similar site on bothIL-17A and IL-17F, allowing for dual inhibition5. Bimekizumab has been approved for use inthe treatment of plaque psoriasis6, psoriatic arthritis7, and axial spondyloarthritis8.

≥ 5.0 mg/ml

Th17 cells, which are CD4 + T-helper cells, are the principal source of IL-17. Tc17 cells, which are CD8 + cells, also make IL-17. Additionally, IL-17 is produced by anumber of innate immune subsets (γδ-T cells, some natural killer T (NKT) cells, TCRβ+‘natural’ Th17 cells, and Type 3 “innate lymphoid cells” (ILC3)) and possibly by myeloid cellsin small amounts.